Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 18Unknown 6Terminated 6Recruiting 5Not yet recruiting 3Withdrawn 2Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 369Neoplasms 253Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 192Lung Neoplasms 140Colorectal Neoplasms 137Neoplasm Metastasis 132Pancreatic Neoplasms 131Leukemia, Myeloid, Acute 126Multiple Myeloma 122Lymphoma 114Carcinoma, Hepatocellular 111Ovarian Neoplasms 98Melanoma 97Recurrence 93Leukemia 88Head and Neck Neoplasms 88Leukemia, Lymphocytic, Chronic, B-Cell 86Brain Neoplasms 86Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Glioblastoma 77Lymphoma, Non-Hodgkin 73Squamous Cell Carcinoma of Head and Neck 71Lymphoma, Follicular 70Lymphoma, Large B-Cell, Diffuse 66Colonic Neoplasms 66Carcinoma, Renal Cell 61Hematologic Neoplasms 59Sarcoma 55Glioma 53

Interventions

cemiplimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Advanced Malignancies × Clear all
NCT05245916 2023-09-05

IBI397 or Combination Therapies in Patients With Advanced Malignancies

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Withdrawn

Advanced Malignancies

NCT02520245 2016-11-07

Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study

Regeneron Pharmaceuticals

Phase 1 Withdrawn

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡